Abstract
Nuclear erythroid factor 2 like 2 (Nrf2) has been described as a transcription factor that serves as a master regulator of the adaptive response to exogenous and endogenous oxidative and electrophilic stresses. Evidence of Nrf2 crosstalk with other molecular pathways is increasing; recent publications have proposed a role of Nrf2 in the development of obesity and in the highly regulated process of adipocyte differentiation through its interaction with other transcription factors and receptors implicated in metabolic regulation. In the present review, we discuss the available data on the possible role of Nrf2 in obesity and metabolic syndrome and the feasibility of using Nrf2 as a therapeutic target in the clinical setting.
Keywords: Diabetes, Keap1, Metabolism, Nrf2, obesity, Oxidative stress, endogenous, exogenous, Body Mass Index, sulfonylureas.
Current Diabetes Reviews
Title:New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Volume: 9 Issue: 2
Author(s): Dionysios V. Chartoumpekis and Thomas W. Kensler
Affiliation:
Keywords: Diabetes, Keap1, Metabolism, Nrf2, obesity, Oxidative stress, endogenous, exogenous, Body Mass Index, sulfonylureas.
Abstract: Nuclear erythroid factor 2 like 2 (Nrf2) has been described as a transcription factor that serves as a master regulator of the adaptive response to exogenous and endogenous oxidative and electrophilic stresses. Evidence of Nrf2 crosstalk with other molecular pathways is increasing; recent publications have proposed a role of Nrf2 in the development of obesity and in the highly regulated process of adipocyte differentiation through its interaction with other transcription factors and receptors implicated in metabolic regulation. In the present review, we discuss the available data on the possible role of Nrf2 in obesity and metabolic syndrome and the feasibility of using Nrf2 as a therapeutic target in the clinical setting.
Export Options
About this article
Cite this article as:
Chartoumpekis V. Dionysios and Kensler W. Thomas, New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome, Current Diabetes Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573399811309020005
DOI https://dx.doi.org/10.2174/1573399811309020005 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion
Current Drug Targets Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy An Overview on the Pharmacokinetics of Quantum Dots
Current Drug Metabolism Sentinel Node Imaging
Current Medical Imaging Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Current Medicinal Chemistry Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Thiosemicarbazones as Potent Anticancer Agents and their Modes of Action
Mini-Reviews in Medicinal Chemistry Saccharomyces Cerevisiae as a Genetic Model in Anticancer Therapy
Current Pharmacogenomics Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics The Mouse In Cancer Research Past, Present, Future
Current Genomics Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Electrically-Assisted Nucleic Acids Delivery to Tissues In Vivo: Where Do We Stand?
Current Pharmaceutical Design A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry